BioNxt Solutions (CSE: BNXT) received a share price boost today after announcing the European Patent Office and its Eurasian counterpart have waved through core claims tied to the company’s sublingual cladribine thin-film formulation — a treatment aimed at relapsing-remitting multiple sclerosis (RRMS).
The pending patents don’t just cover the MS-specific delivery tech. They also stretch across a broader range of chemotherapy drugs in oral-dissolvable formats for neurological autoimmune diseases. That’s not just patent coverage — that’s an entire platform grab.
Europe said yes. Eurasia said yes. Investors said “how high?”
BNXT surged big on the news, validating the long tail on its IP strategy and giving holders a 21% jump on the day, settling at $0.97 after briefly hitting $1.10, up from $0.71 at yesterday’s close.
The stock was sitting under $0.20 in September of last year, when management changes and the patent strategy were announced. As recently as two weeks ago, it sat at $0.55, before torquing through today.
Why This Mattered:
-
The science: Sublingual thin-film = no injections, better absorption, better compliance, and a faster ride to market in regions where convenience matters.
-
The IP: The EPO confirmed BioNxt’s claims of clear novelty, inventiveness, and industrial use hurdles. Eurasia also signed off, covering eight countries across Eastern Europe and Central Asia.
-
The strategy: BioNxt already moved the patent into the national phase for other key markets — US, Canada, Japan, Australia, and New Zealand.
Next Stops on the Runway:
-
Full grant and publication of the patents.
-
GMP manufacturing ramp-up.
-
Human bioequivalence study in Europe — this is where the science and paperwork start translating into regulatory filings and, eventually, product on shelves.
Long time readers will remember this outfit as formerly being XPhyto, a cannabis pharma research outfit that, way back in the day, had planned to grow weed in old Nazi WWII bunkers. They’ve come a long way since and, to their credit, have built a real pharamceutical IP company here.
If you were waiting to see if this team had the chops to play outside the microcap sandbox, this week was your answer.
IP wins in pharma don’t just add value, they lock it in. Expect licensing convos to follow — and if they’ve got trial data to match the IP hype, you might just have a mover worth riding long.
BNXT’s thin-film story just got a lot thicker.
— Chris Parry
Leave a Reply